Highland Therapeutics Inc.’s wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), today announced positive clinical data from the second Phase 3 pivotal trial of its investigational drug product, HLD-200 (delayed-release and extended-release methylphenidate capsules).
